AR088844A1 - IMMEDIATE RELEASE FORMULATION OF 4-METHYL-3 - [[4- (3-PIRIDINIL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METIL) -FENIL] -BENZAMIDA - Google Patents
IMMEDIATE RELEASE FORMULATION OF 4-METHYL-3 - [[4- (3-PIRIDINIL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METIL) -FENIL] -BENZAMIDAInfo
- Publication number
- AR088844A1 AR088844A1 ARP120104259A ARP120104259A AR088844A1 AR 088844 A1 AR088844 A1 AR 088844A1 AR P120104259 A ARP120104259 A AR P120104259A AR P120104259 A ARP120104259 A AR P120104259A AR 088844 A1 AR088844 A1 AR 088844A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- imidazol
- trifluoro
- pyrimidinyl
- amino
- Prior art date
Links
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000007909 solid dosage form Substances 0.000 abstract 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 229960001346 nilotinib Drugs 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se da a conocer una forma de dosificación sólida del nilotinib que comprende: (i) un núcleo que comprende la 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-N-[5-(4-metil-1H-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida, o una sal farmacéuticamente aceptable de la misma, y excipientes; y (ii) cuando menos un polímero, recubriendo este polímero al núcleo, en donde se demora la desintegración de la forma de dosificación sólida mencionada.A solid dosage form of nilotinib is disclosed comprising: (i) a core comprising 4-methyl-3 - [[4- (3-pyridinyl) -2-pyrimidinyl] -amino] -N- [5 - (4-methyl-1H-imidazol-1-yl) -3- (trifluoro-methyl) -phenyl] -benzamide, or a pharmaceutically acceptable salt thereof, and excipients; and (ii) at least one polymer, coating this polymer to the core, where the disintegration of the mentioned solid dosage form is delayed.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559281P | 2011-11-14 | 2011-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088844A1 true AR088844A1 (en) | 2014-07-10 |
Family
ID=47324402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104259A AR088844A1 (en) | 2011-11-14 | 2012-11-12 | IMMEDIATE RELEASE FORMULATION OF 4-METHYL-3 - [[4- (3-PIRIDINIL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METIL) -FENIL] -BENZAMIDA |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP2779995A1 (en) |
| JP (1) | JP6275645B2 (en) |
| KR (1) | KR20140093230A (en) |
| CN (1) | CN103930094A (en) |
| AR (1) | AR088844A1 (en) |
| BR (1) | BR112014011518A2 (en) |
| CA (1) | CA2855503A1 (en) |
| CL (1) | CL2014001247A1 (en) |
| CO (1) | CO6960546A2 (en) |
| EA (1) | EA201490960A1 (en) |
| GT (1) | GT201400094A (en) |
| HK (1) | HK1197025A1 (en) |
| IL (1) | IL232480A0 (en) |
| IN (1) | IN2014DN03416A (en) |
| MA (1) | MA35636B1 (en) |
| MX (1) | MX2014005874A (en) |
| PE (1) | PE20141337A1 (en) |
| PH (1) | PH12014501062B1 (en) |
| SG (2) | SG11201401476TA (en) |
| TN (1) | TN2014000177A1 (en) |
| TW (1) | TWI574690B (en) |
| WO (1) | WO2013074432A1 (en) |
| ZA (1) | ZA201402756B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CZ2017821A3 (en) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Dosing of crystalline nilotinib |
| JP7378279B2 (en) * | 2019-11-18 | 2023-11-13 | 日本化薬株式会社 | Pharmaceutical tablet containing nilotinib as an active ingredient and method for producing the same |
| JP7489849B2 (en) * | 2020-07-20 | 2024-05-24 | 日本化薬株式会社 | Nilotinib tablets |
| JP7776274B2 (en) * | 2021-07-19 | 2025-11-26 | 日本化薬株式会社 | Nilotinib tablets and their manufacturing method |
| JP7776275B2 (en) * | 2021-07-26 | 2025-11-26 | 日本化薬株式会社 | Nilotinib tablets and their manufacturing method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GT200600316A (en) | 2005-07-20 | 2007-04-02 | SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA. | |
| GT200600315A (en) | 2005-07-20 | 2007-03-19 | CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA | |
| EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| IN2011CH01887A (en) * | 2011-06-02 | 2012-12-14 |
-
2012
- 2012-11-12 KR KR1020147012521A patent/KR20140093230A/en not_active Ceased
- 2012-11-12 PH PH1/2014/501062A patent/PH12014501062B1/en unknown
- 2012-11-12 AR ARP120104259A patent/AR088844A1/en unknown
- 2012-11-12 SG SG11201401476TA patent/SG11201401476TA/en unknown
- 2012-11-12 SG SG10201707768RA patent/SG10201707768RA/en unknown
- 2012-11-12 IN IN3416DEN2014 patent/IN2014DN03416A/en unknown
- 2012-11-12 HK HK14110470.2A patent/HK1197025A1/en unknown
- 2012-11-12 EP EP12798500.0A patent/EP2779995A1/en not_active Withdrawn
- 2012-11-12 JP JP2014541363A patent/JP6275645B2/en not_active Expired - Fee Related
- 2012-11-12 WO PCT/US2012/064610 patent/WO2013074432A1/en not_active Ceased
- 2012-11-12 EA EA201490960A patent/EA201490960A1/en unknown
- 2012-11-12 CN CN201280055937.8A patent/CN103930094A/en active Pending
- 2012-11-12 MX MX2014005874A patent/MX2014005874A/en unknown
- 2012-11-12 BR BR112014011518A patent/BR112014011518A2/en not_active IP Right Cessation
- 2012-11-12 PE PE2014000672A patent/PE20141337A1/en not_active Application Discontinuation
- 2012-11-12 CA CA2855503A patent/CA2855503A1/en not_active Abandoned
- 2012-11-13 TW TW101142278A patent/TWI574690B/en not_active IP Right Cessation
-
2014
- 2014-04-15 ZA ZA2014/02756A patent/ZA201402756B/en unknown
- 2014-04-25 TN TNP2014000177A patent/TN2014000177A1/en unknown
- 2014-05-05 IL IL232480A patent/IL232480A0/en unknown
- 2014-05-07 MA MA36991A patent/MA35636B1/en unknown
- 2014-05-13 CL CL2014001247A patent/CL2014001247A1/en unknown
- 2014-05-14 GT GT201400094A patent/GT201400094A/en unknown
- 2014-05-14 CO CO14103891A patent/CO6960546A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014005874A (en) | 2014-06-23 |
| TN2014000177A1 (en) | 2015-09-30 |
| CO6960546A2 (en) | 2014-05-30 |
| SG10201707768RA (en) | 2017-10-30 |
| EP2779995A1 (en) | 2014-09-24 |
| JP2014533283A (en) | 2014-12-11 |
| NZ623844A (en) | 2016-09-30 |
| CN103930094A (en) | 2014-07-16 |
| IN2014DN03416A (en) | 2015-06-26 |
| BR112014011518A2 (en) | 2017-05-16 |
| PH12014501062A1 (en) | 2014-06-23 |
| TW201325594A (en) | 2013-07-01 |
| KR20140093230A (en) | 2014-07-25 |
| GT201400094A (en) | 2017-09-28 |
| MA35636B1 (en) | 2014-11-01 |
| AU2012339829B2 (en) | 2016-05-12 |
| IL232480A0 (en) | 2014-06-30 |
| ZA201402756B (en) | 2015-04-29 |
| JP6275645B2 (en) | 2018-02-07 |
| TWI574690B (en) | 2017-03-21 |
| WO2013074432A1 (en) | 2013-05-23 |
| CA2855503A1 (en) | 2013-05-23 |
| AU2012339829A1 (en) | 2014-05-29 |
| EA201490960A1 (en) | 2014-08-29 |
| CL2014001247A1 (en) | 2014-10-17 |
| SG11201401476TA (en) | 2014-10-30 |
| PH12014501062B1 (en) | 2018-04-20 |
| PE20141337A1 (en) | 2014-10-16 |
| HK1197025A1 (en) | 2015-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086913A1 (en) | 4-METIL-3 - [[4- (3-PIRIDINIL) -2-PIRIMIDINIL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METIL) -FENIL] -BENZAMIDA AMORFA, FORM OF DOSAGE THAT CONTAINS AND METHOD TO PREPARE | |
| AR088844A1 (en) | IMMEDIATE RELEASE FORMULATION OF 4-METHYL-3 - [[4- (3-PIRIDINIL) -2-PYRIMIDINYL] -AMINO] -N- [5- (4-METHYL-1H-IMIDAZOL-1-IL) -3- (TRIFLUORO-METIL) -FENIL] -BENZAMIDA | |
| PE20141822A1 (en) | INHIBITOR OF APOPTOSIS SIGNAL REGULATORY KINASE | |
| AR122580A2 (en) | DOSAGE FORM OF DOXYLAMINE AND PYRIDOXINE AND/OR THEIR METABOLITES OR SALTS | |
| NZ721298A (en) | Pharmaceutical compositions comprising azd9291 | |
| PH12014501277A1 (en) | Kinase inhibitors | |
| EA201291421A1 (en) | ORAL PHARMACEUTICAL MEDICINE FORMS CONTAINING ETEXILATE DAGIGATRAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| NZ600310A (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
| CY1118327T1 (en) | USE OF A BYU PRODUCTION IN TREATMENT OF ACUTE EXTREMES OF COLD TEMPERATURE | |
| PH12014501278A1 (en) | Kinase inhibitors | |
| EA201590142A1 (en) | PHARMACEUTICAL MEDICINE FORMS CONTAINING 5-CHLOR-N - ({(5S) -2-OXO-3- [4- (3-OXO-4-MORFOLINIL) PHENYL] -1,3-OXAZOZOLIDIN-5-IL} METH) -2-TIOFEN-CARBOXAMID | |
| CO2018002046A2 (en) | New oral delayed dual dexlansoprazole oral composition | |
| WO2012080184A3 (en) | Liquid pharmaceutical compositions which can be administered orally and contain 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophene carboxamide | |
| HRP20171295T1 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) | |
| PH12016500716A1 (en) | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate | |
| TH152470A (en) | Recipe formula 4- methyl-3 - ((4- (3-pyridyl-2-pyrimidinyl-amino) 1-N- (5- (4-methyl-1H-imi Dasol-1-il) -3- (trifluoromethyl) phenyl] benzamide instant release. | |
| TN2013000440A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| HRP20201574T1 (en) | SUBSTITUTED NICOTINIMIDE BTK INHIBITORS, THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASES | |
| TN2014000218A1 (en) | Kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |